🏛️ Verified NIH Record • Updated 2025-01-07
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (NCT05688280)
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. A Multicenter Phase 1b/2a Trial in Colorectal Cancer, Non-small Cell Lung Cancer, and Soft Tissue Sarcoma Patients
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Immunophotonics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
Who can join: Review the eligibility criteria below.
Location: Miami Cardiac & Vascular Institute — Coral Gables, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Miami Cardiac & Vascular Institute — Coral Gables, Florida
- University of Louisville Physicians, PSC — Louisville, Kentucky
- Stephenson Cancer Center — Oklahoma City, Oklahoma
- Institut Bergonie — Bordeaux,
- Hospitalier Pitie-Salpetriere — Paris,
- Hôpital Foch — Suresnes,
- Institut Gustave Roussy — Villejuif,
- Johann Wolfgang Goethe-Univresitat Frankfurt/Main — Frankfurt,
- SLK-Kliniken Heilbronn GmbH — Heilbronn,
- Munchen Klinik Bogenhausen — Munich,
- IOSI Ospedale San Giovanni Bellinzona — Bellinzona,
- Inselspital Universitatsspital, Bern — Bern,
- Kantonsspital Graubunden — Chur,
- Kantonsspital St. Gallen — Sankt Gallen,
- University College London Hospitals — London,
- Churchill Hospital — Oxford,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Solid Tumor
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors — Orlando, Florida
- Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) — Baltimore, Maryland
- TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) — Los Angeles, California
- Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors — Anchorage, Alaska
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors — El Segundo, California
Explore by condition: All Metastatic Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.